reddit.com· r/biotech · Reddit·· 5 hours agoPickScore85
Moderna/Merck’s melanoma vaccine shows 42% reduction in mortality or recurrence
In brief
Phase 3 INTerpath-001 showed that Moderna's personalized neoantigen vaccine intismeran autogene combined with Merck's Keytruda reduced the risk of melanoma recurrence or death by 42%, with an HR of 0.58, and reduced the risk of metastasis by 38%.
Why it matters
The material gives two-year cancer-free rates for the combination versus Keytruda alone as context for the 42% risk reduction.
Source: reddit.com · reddit.com